Cardiology · 2002 · 42 citations · 14 references
MedicinePharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPharmacodynamicsCardiac MedicationsCardiac PharmacotherapyCardiovascular Drug SafetyCardiovascular PharmacologyHeart FailureHeart Failure PharmacotherapyCardiac IndexCardiac Systolic FunctionDouble-blind TrialsPilot TrialsRelaxation Time MeasurementsSystolic DysfunctionThyroid Hormone AnaloguesVascular Resistance
After an initial safety study in 7 normal volunteers, a randomized double-blind comparison was made between 3,5-diiodothyropropionic acid (DITPA) and placebo in 19 patients with moderately severe congestive failure. In heart failure patients receiving the drug for 4 weeks, cardiac index was increased (p = 0.04) and systemic vascular resistance index was decreased (p = 0.02). Systolic cardiac function was unchanged but isovolumetric relaxation time was decreased significantly, suggesting improvement in diastolic function. Total serum cholesterol (p = 0.005) and triglycerides (p = 0.01) also were decreased significantly. DITPA could represent a useful new agent for treatment of congestive heart failure.
14
Changing epidemiological features of cardiac failure
William B. Kannel, Kalon K.L. Ho, Thomas Thom · Heart · 1994 · 337 citations · Full text
A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity
A. H. Underwood, J. C. EMMETT, David A. Ellis et al. · Nature · 1986 · 131 citations